B+
Bull case
25%
Probability
Target price
$1.10
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
NSPR
InspireMDFNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$0.55
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.20
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-10
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+38.6
Score
AI commentary
The positive regulatory pathway is offset by recall losses, cash consumption and warrant overhang. Supplied news is from August; no reliable recent price reaction, analyst revisions or measured social, options, short-interest or employee readings were available. Numeric zero sentiment fields mean unavailable, not measured neutrality. [#SEC-8K-2026-08-17] [#8-K-2026-09-21]
RankAlpha Sentiment Codex - 2026-10-10
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventCGuard Prime 80 cm FDA decisionHigh impact
Management anticipated an FDA decision in 2026 for the TCAR stent. Approval could enable a U.S. launch, but timing and outcome remain uncertain. The September warrant amendments also make an approval announcement a potential trigger for warrant exercise. [#SEC-8K-2026-08-17] [#8-K-2026-09-21]
2026-12-31eventOriginal CGuard CAS regulatory decisionHigh impact
Management separately anticipated a 2026 FDA decision for the original CGuard platform for traditional carotid stenting. Approval could broaden U.S. launch options; commercial adoption would still need to be demonstrated. [#SEC-8K-2026-08-17]
2026-12-31eventRecalled 135 cm delivery-system submissionHigh impact
Design changes following the voluntary recall were undergoing validation and performance testing, with an FDA submission anticipated before year-end. A submission would not establish approval or a relaunch date. [#SEC-8K-2026-08-17] [#EARNINGS-TRANSCRIPT-2026Q2]
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-10 • Updated nightlySource: Internal modelMethodology